FDA Offers Guidance On AI In Health Care & Medical Product Development

The U.S. Food & Drug Administration (FDA) released guidance to its medical product centers on development and use of artificial intelligence (AI) across the medical product life cycle to foster responsible innovation for AI used in medical products. The FDA’s medical product centers concerned with AI are its Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH), and Office of Combination Products (OCP).

The FDA focused on four priorities for its medical product centers:

• Fostering collaboration to safeguard public health . . .
  
  Restricted Content

  You must be an Elite member to view this resource.

  Log In | Sign up or learn more about membership options.